
    
      This is a 4-period, 4-sequence single dose crossover study. Each participant will participate
      in 4 treatment periods separated by a washout of at least 7 days between study drug
      administrations in each period. Participants will be randomized to 1 of 4 sequences.

      Participants will be screened for up to 21 days prior to study drug administration on day 1
      of period 1. Eligible participants will be admitted to the clinical unit on day -1 of each
      period and will be residential for 5 days/4 nights.

      Participants will receive a single dose of 100 mg roxadustat pediatric azo dye-free tablet,
      100 mg roxadustat pediatric azo dye-free mini-tablet (suspension), 100 mg roxadustat
      pediatric azo dye-free mini-tablet (solid) (new formulations) or 100 mg roxadustat azo
      dye-containing tablet (reference formulation) under fasting conditions on day 1 of each
      period.
    
  